The pipeline of new molecules and regimens against drug-resistant tuberculosis

The clinical development and regulatory approval of bedaquiline, delamanid and pretomanid over the last decade brought about significant progress in the management of drug-resistant tuberculosis, providing all-oral regimens with favorable safety profiles. The Nix-TB and ZeNix trials of a bedaquiline...

Descripción completa

Detalles Bibliográficos
Autores principales: Black, Todd A., Buchwald, Ulrike K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593651/
https://www.ncbi.nlm.nih.gov/pubmed/34816020
http://dx.doi.org/10.1016/j.jctube.2021.100285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593651/
https://www.ncbi.nlm.nih.gov/pubmed/34816020
http://dx.doi.org/10.1016/j.jctube.2021.100285

Ejemplares similares